GPC3 127–136 -HSP70 mRNA Nanovaccine in Combination with Anti-PD-L1 Therapy Elicits Robust T-Cell-Mediated Immunity against Hepatocellular Carcinoma
ACS Biomaterials Science & Engineering · 2026
DOI: 10.1021/acsbiomaterials.5c01444 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, 2026. Verfasst von Peng Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, College of High Altitude Military Medicine, Army Medical University, Chongqing 400038, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, HSP70 Heat-Shock Proteins, Glypicans. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) remains a clinically challenging malignancy, and it is imperative to develop novel therapeutic strategies for HCC treatment. In this study, we developed a novel mRNA-based nanovaccine (SK-mRNA) targeting the tumor-associated antigen glypican-3 (GPC3). The SK-mRNA vaccine consists of in vitro -transcribed mRNA encoding 3 × GPC3 127–136 CTL epitopes fused with HSP70, which self-assembles with the cationic peptide SP94-GGG-K18 to form a uniform spherical nanostructure. This nanovaccine facilitates the targeted delivery of mRNA to tumors via SP94 binding with its cognate receptor on tumor cells, enabling the expression and secretion of the 3 × GPC3 127–136 -HSP70 fusion protein. Subsequently, dendritic cells internalize this protein through its receptors on dendritic cells, leading to the presentation of CTL epitope GPC3 127–136 to T cells. Experimental vaccination elicited robust antigen-specific T-cell responses, as evidenced by the significant increase in CD8 + T cells observed in both spleens and tumors, along with enhanced IFN-γ secretion in response to the GPC3 127–136 peptide. The combination of SK-mRNA nanovaccine with anti-PD-L1 immunotherapy exhibited potent synergistic antitumor effects. These findings collectively suggest that SK-mRNA nanovaccines can effectively stimulate immune responses and synergize with immune checkpoint blockade therapies to mediate powerful antitumor effects, offering a promising strategy for the effective treatment of HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathophysiology, College of High Altitude Military Medicine, Army Medical University, Chongqing 400038, China.
- Medical Research Institute, Southwest University, Chongqing 400700, China.
- State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.
- Department of Rehabilitation, Southwest Hospital, Army Medical University, Chongqing 400038, China.
ORCID-Profile: Hongjuan Cui, Bing Ni
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, P., Dong, R., Zhang, M., Liao, J., Liu, P., Lei, B., Cui, H., Peng, Y., & Ni, B. (2026). GPC3 127–136 -HSP70 mRNA Nanovaccine in Combination with Anti-PD-L1 Therapy Elicits Robust T-Cell-Mediated Immunity against Hepatocellular Carcinoma. ACS Biomaterials Science & Engineering. https://doi.org/10.1021/acsbiomaterials.5c01444
Vancouver
Wang P, Dong R, Zhang M, Liao J, Liu P, Lei B, et al. GPC3 127–136 -HSP70 mRNA Nanovaccine in Combination with Anti-PD-L1 Therapy Elicits Robust T-Cell-Mediated Immunity against Hepatocellular Carcinoma. ACS Biomaterials Science & Engineering. 2026. doi:10.1021/acsbiomaterials.5c01444
BibTeX
@article{Wang2026,
author = {Wang, Peng and Dong, Rui and Zhang, Mengjie and Liao, Jingyi and Liu, Paiyu and Lei, Bo and Cui, Hongjuan and Peng, Yanmeng and Ni, Bing},
title = {GPC3 127–136 -HSP70 mRNA Nanovaccine in Combination with Anti-PD-L1 Therapy Elicits Robust T-Cell-Mediated Immunity against Hepatocellular Carcinoma},
journal = {ACS Biomaterials Science & Engineering},
year = {2026},
doi = {10.1021/acsbiomaterials.5c01444}
}
EUVIMED